Delving into the Latest Updates on Beta Pharma (Suzou) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CDK4 x CDK6	1

BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and CDK6 kinase activity. This Phase I study is a first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of oral BPI-1178 in patients with advanced solid tumors. The Phase IIa trial is designed to investigate the anti-tumor activity and safety of BPI-1178 in combination with endocrine therapy in patients with HR+/HER2-advanced breast cancer and to determine the dosing regimen for combination with endocrine therapy in a later confirmatory study.

Start Date15 Jun 2020

Sponsor / Collaborator

Beta Pharma (Suzou) Co., Ltd.

100 Clinical Results associated with Beta Pharma (Suzou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beta Pharma (Suzou) Co., Ltd.

Login to view more data

100 Deals associated with Beta Pharma (Suzou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beta Pharma (Suzou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Login to view more data